Weight loss and diabetes may just be the beginning for drugs like Ozempic, Wegovy, Mounjaro and Zepbound as reports increasingly suggest they may have far-reaching benefits for treating conditions as diverse as heart disease, liver disease, Parkinson’s, sleep apnea and addiction, sparking research among firms competing in pharma’s latest gold rush.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
